COMMUNIQUÉS West-GlobeNewswire

INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology
17/12/2018
Transformational momentum building as Company plans to apply for two NDAs in 2019 PHOENIX, Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and [...]
Arrayit Corporation Fulfills Clinical Instrumentation Contract with the United States Food and Drug Administration
17/12/2018
Sunnyvale, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, reports fulfillment of a clinical instrumentation contract with the United States Food [...]
Change to Executive Management – Jakob Gudbrand appointed CEO of GN Hearing
17/12/2018
Today, GN Store Nord announces the appointment of Jakob Gudbrand as CEO of GN Hearing and member of GN Store Nord’s Executive Management, effective as of 18 February 2019. Jakob comes to GN from a position as President [...]
Olainfarm Group Sales in November Grew By 8%
17/12/2018
Preliminary consolidated results of JSC Olainfarm for November 2018 show that total sales of the Group have reached 10.9 million euros, which represents 8% increase compared to the same period of 2018. During the eleven [...]
GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
17/12/2018
GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommended the continuation of RESOLVE-IT without any modifications [...]
GENFIT : Issue positive du DSMB à 30 mois, recommandant la poursuite de l'étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH
17/12/2018
GENFIT : Issue positive du DSMB à 30 mois, recommandant la poursuite de l'étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH Le Data Safety Monitoring Board (DSMB) a recommandé la poursuite de l' [...]
Proposed Subscription to Raise $25m and Notice of General Meeting
17/12/2018
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY [...]
NeuroSearch – financial calendar for 2019
17/12/2018
Announcement 17 December 2018 NeuroSearch A/S (NEUR) hereby announces the company’s financial calendar for 2019. 8 March 2019 Annual Report 2018 29 April 2019 Annual General Meeting 30 August 2019 Interim report for H1 [...]
Summit Therapeutics Announces Departure of Chief Financial Officer
17/12/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics Announces Departure of Chief Financial Officer Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: [...]
Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting
17/12/2018
In 2017 and 2018, Oasmia has had a number of successful developments. Oasmia is currently in a phase where it has positive momentum with many ongoing activities. Two of Oasmia’s major shareholders, Per Arwidsson and [...]
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
17/12/2018
Delivery via inhalers could dramatically expand clinical utility and commercial opportunity for RPL554 LONDON, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical [...]
Farmako: Biggest non-Canadian investment in Europe to date With Seven-digit Investment by Heartbeat Labs
17/12/2018
Frankfurt-based pharmaceutical company in the cannabis sector receives seven-digit seed funding from German health tech platform Heartbeat Labs First seven-digit investment for a European company in that industry by a [...]
Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market
17/12/2018
Press Release Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market ............................................... Accesses the fast-growing [...]
Nicox : signature d'un accord de licence exclusif avec Ocumension Therapeutics pour le développement et la commercialisation de NCX 470 sur le marché chinois
17/12/2018
Communiqué de presse Nicox : signature d'un accord de licence exclusif avec Ocumension Therapeutics pour le développement et la commercialisation de NCX 470 sur le marché chinois [...]
BIOPHYTIS Strengthens its Senior Management Team and Continues its Expansion in the United States
17/12/2018
PARIS, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris : ALBPS), a biotechnology company developing drug candidates to reduce disabilities caused by age-related and genetic degenerative diseases, [...]
VALNEVA Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
17/12/2018
Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate Saint-Herblain (France), December 17, 2018 - Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for [...]
VALNEVA lance la Phase 2 du développement de son vaccin contre la maladie de Lyme
17/12/2018
Valneva lance la Phase 2 du développement de son vaccin contre la maladie de Lyme Saint-Herblain (France), 17 décembre 2018 - Valneva SE ("Valneva"), société de biotechnologie développant et commercialisant des vaccins [...]
Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)
15/12/2018
Second EBV‑associated solid tumor with encouraging responses to tab-cel ® Tab-cel ® safety appears consistent with a favorable risk profile and previous observations Results were presented today in an oral session at [...]
BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress
15/12/2018
CAMBRIDGE, Mass. and BEIJING, China, Dec. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

Pages